Pennsylvania Society of Oncology and Hematology - Home
The Pennsylvania Society of Oncology and Hematology represents more than 200 physicians and other health care professionals who care for cancer patients. The Society is a non-profit corporation devoted to the improvement of hematologic and oncologic care of patients.
2024 Abstracts - Pennsylvania Society of Oncology and Hematology
Maximum two abstracts per author. Your abstract presentation is a vital and vibrant part of our annual conference. It is your opportunity to showcase your research, sharpen your presentation skills, and meet with attendings, directors and peers.
Events - Pennsylvania Society of Oncology and Hematology
2024 Meeting Information. We hope you are able to join us for the 2024 PSOH Annual Meeting. Please click below for additional information. Attendees. Exhibitors. Abstracts.
Membership - Pennsylvania Society of Oncology and Hematology
The PSOH website at www.psoh.org and social media provide members with up-to-date information on the Society’s upcoming events, Medicare changes, and legislative and regulatory issues. It also has a job bank for career opportunity listings.
About Us - Pennsylvania Society of Oncology and Hematology
PSOH is an organization of physicians and health care professionals devoted to the improvement of hematologic and oncologic care of patients. The Society’s specific missions include: Communications
Exhibitors - Pennsylvania Society of Oncology and Hematology
Jul 1, 2024 · PSOH offers a variety of support opportunities for its 2024 Annual Meeting on Friday, October 25th. To discover all the ways you can showcase your company to practicing medical, surgical, and radiation oncologists, including nurse oncologists, download the …
Officers - Pennsylvania Society of Oncology and Hematology
To email the Executive Board or any of the PSOH Staff, please use our Contact Us form.
2023 Posters - Pennsylvania Society of Oncology and Hematology
Click on the title of the poster for a full-screen view. Outcomes Among Hospitalized Patients with Relapsing Multiple Myeloma Utilizing Palliative Care: A United States Population-Based Cohort Study. Yajur Arya (1) MD, Arshi Syal (1) MD, Bruce Adrian Casipit (1) MD, Claudia Dourado (2) MD, Gordon Heller (1) DO.
Malignant pleural effusion is present in more than 15% patients at time of diagnosis of lung cancer. Median survival - 4.3 months. Management - mostly palliative but helps lower hospital stay and inpatient mortality. Aim of this study is to identify inpatient mortality in patients with malignant pleural effusion.
Outcomes among hospitalized patients with acute chest syndrome and concomitant clinical depression: A United States population-based Cohort Study. Arshi Syal1 MD, Yajur Arya1 MD, Bruce Adrian Casipit1 MD, Claudia Dourado2 MD, Gordon Heller1 DO.